Cytocares Inc

This early-stage study tests a new drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is not a cure, but a…

This early study tests the safety of a new drug, CC312, in 6 adults with lupus, myositis, or scleroderma that has come back or not responded to standard treatments. The main goal is to check for side effects, not to cure the disease. Participants will receive multiple doses of th…

This early-stage study tests the safety of a new drug called CC312 in 18 adults with autoimmune diseases like lupus and rheumatoid arthritis that haven't responded to standard treatments. CC312 works like a 'biological CAR-T' by guiding immune cells to attack and deplete faulty B…

This early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to check safety and how the body handles the drug, not to cure the disease. Participants will receive either CC312 or a placebo, and researchers will monitor side eff…